Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.

To begin to build an understanding of the interactions of CYP2B6 with substrates, two different 3-dimensional quantitative structure activity relationship (3D-QSAR) models were constructed using 16 substrates of B-lymphoblastoid expressed CYP2B6. A pharmacophore model was built using the program Catalyst, which was compared with a partial least-squares (PLS) model using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors. The Catalyst model yielded a 3-dimensional model of the common structural features of CYP2B6 substrates, whereas PLS MS-WHIM generated a model based on statistical analyses of molecular descriptors for size and shape of the substrate. The pharmacophore model obtained with Catalyst consisted of three hydrophobes and one hydrogen bond acceptor region. The cross-validated PLS MS-WHIM model gave a good q2 value of 0.607. Size, positive electrostatic potential, hydrogen bonding acceptor capacity, and hydrophobicity were found to be the most relevant descriptors for the model. These models were then used to predict the Km (apparent) values of a test set of structurally diverse substrates for CYP2B6 not included in the model building, specifically lidocaine, amitriptyline, bupropion, arteether, and verapamil. Overall, both 3D-QSAR methods yielded satisfactory Km (apparent) value predictions for the majority of the molecules in the test set. However, PLS MS-WHIM was unable to reliably predict the Km (apparent) value for verapamil, whereas Catalyst did not predict the Km (apparent) value for lidocaine. In both of these cases the residual of the Km (apparent) value was greater than one log unit. The strengths and limitations of both of these 3D-QSAR approaches are discussed.

[1]  C. Hansch,et al.  Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.

[2]  Stephen L. Rodgers,et al.  Prediction of Molecular Properties. , 1987 .

[3]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[4]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[5]  C. Hansch,et al.  QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.

[6]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[7]  T. Aoyama,et al.  Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  Gianpaolo Bravi,et al.  Application of MS-WHIM Descriptors: 3. Prediction of Molecular Properties , 2000 .

[9]  J. Peggins,et al.  Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[10]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[11]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[12]  G. Nelsestuen,et al.  Steady state enzyme velocities that are independent of [enzyme]: an important behavior in many membrane and particle-bound states. , 1997, Biochemistry.

[13]  P. Beaune,et al.  Inter-individual variability in the oxidation of 1,2-dibromoethane: use of heterologously expressed human cytochrome P450 and human liver microsomes. , 1996, Chemico-biological interactions.

[14]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[15]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[16]  S L Lin,et al.  Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. , 1997, Journal of medicinal chemistry.

[17]  D. Rogers,et al.  Receptor surface models. 2. Application to quantitative structure-activity relationships studies. , 1995, Journal of medicinal chemistry.

[18]  J. Snyder,et al.  7 – Modeling Drug–Receptor Interactions , 1996 .

[19]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[20]  J. Stevens,et al.  Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Roberto Todeschini,et al.  MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids , 1997, J. Comput. Aided Mol. Des..

[22]  S. Ekins,et al.  Examination of purported probes of human CYP2B6. , 1997, Pharmacogenetics.

[23]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[24]  Gianpaolo Bravi,et al.  Application of MS‐WHIM Descriptors: 1. Introduction of New Molecular Surface Properties and 2. Prediction of Binding Affinity Data , 2000 .

[25]  G. Tucker,et al.  Cytochromes P450 mediating the N-demethylation of amitriptyline. , 2003, British journal of clinical pharmacology.

[26]  K. Uchino,et al.  Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. , 1996, Biological & pharmaceutical bulletin.

[27]  H. Yamazaki,et al.  7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. , 1996, Biochemical pharmacology.

[28]  T Ishizaki,et al.  Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  S. Wold,et al.  PLS: Partial Least Squares Projections to Latent Structures , 1993 .

[30]  I. H. Segel.  Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[31]  D. Lewis,et al.  Molecular modelling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[33]  J. Stevens,et al.  Human liver CYP2B6-catalyzed hydroxylation of RP 73401. , 1997, The Journal of pharmacology and experimental therapeutics.

[34]  J. Gasteiger,et al.  Autocorrelation of Molecular Surface Properties for Modeling Corticosteroid Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks , 1995 .

[35]  J. G. Snijders,et al.  Extension of a predictive substrate model for human cytochrome P4502D6. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[36]  U. Hofmann,et al.  Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation , 1996, Clinical pharmacology and therapeutics.